13 pending office actions • 8 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Takeda Pharmaceutical Company Limited | 3 |
| Numab Therapeutics AG | 3 |
| Aslan Pharmaceuticals Pte Ltd | 2 |
| Aslan Pharmaceuticals Pte Ltd | 1 |
| Hoffmann-La Roche, Inc. | 1 |
| Bio-Gate AG | 1 |
| Almirall, S.A. | 1 |
| Julius-Maximilians-Universitaet Wuerzburg | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18695464 | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF | Aslan Pharmaceuticals Pte Ltd | LOCKARD, JON MCCLELLAND | 1647 | Final Rejection | Mar 26, 2024 |
| 18550504 | INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited | DEKARSKE, MADELINE MCGUIRE | 1622 | Non-Final OA | Sep 14, 2023 |
| 18550474 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited | DEKARSKE, MADELINE MCGUIRE | 1622 | Non-Final OA | Sep 14, 2023 |
| 18550571 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited | ROBINSON, MIKHAIL O'DONNEL | 1627 | Non-Final OA | Sep 14, 2023 |
| 18263753 | MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR ROR1 AND CD3 | Numab Therapeutics AG | DUFFY, BRADLEY | 1643 | Non-Final OA | Aug 01, 2023 |
| 18258957 | ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY | Numab Therapeutics AG | MELCHIOR, JAMES RYLAND | 1644 | Non-Final OA | Jun 22, 2023 |
| 18317385 | DUAL TARGETING | Hoffmann-La Roche, Inc. | MOSELEY II, NELSON B | 1642 | Non-Final OA | May 15, 2023 |
| 18252906 | FILTER MATERIAL FOR FILTERING A FLUID | Bio-Gate AG | RUDDIE, ELLIOT S | 3785 | Non-Final OA | May 15, 2023 |
| 18249224 | TREATMENT OF AUTOIMMUNE DISEASES WITH A DIHYDROOROTATE HEHYDROGENASE (DHODH) INHIBITOR | Almirall, S.A. | PIHONAK, SARAH | 1627 | Non-Final OA | Apr 14, 2023 |
| 18042920 | TREATMENT AND/OR PREVENTION OF A VIRAL INFECTION | Aslan Pharmaceuticals Pte Ltd | ROMERO, KRISTEN WANG | 1624 | Non-Final OA | Feb 24, 2023 |
| 17906184 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | Julius-Maximilians-Universitaet Wuerzburg | MAHLUM, JONATHAN DAVIS | 1625 | Non-Final OA | Sep 12, 2022 |
| 17929874 | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION | Aslan Pharmaceuticals Pte Ltd | BRISTOL, LYNN ANNE | 1643 | Final Rejection | Sep 06, 2022 |
| 17822959 | NOVEL ANTIBODY FRAMEWORKS | Numab Therapeutics AG | BRISTOL, LYNN ANNE | 1643 | Non-Final OA | Aug 29, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial